[Mycoplasma pneumoniae的复苏:一个新的流行病?]
Kenza Bouras1, Jacques Schrenzel2,3, Adrien Fischer2
1Service de médecine interne, Hôpital de La Tour, 1217 Meyrin/Genève.
Revue medicale suisse
|November 15, 2024
概括
在全球范围内,Mycoplasma pneumoniae肺炎的病例正在激增,影响儿童和成年人. 虽然亚洲的宏类耐药性很高,但欧洲的耐药性率仍然很低,这表明该地区的有效治疗选择.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 流行病学 流行病学
背景情况:
- 菌性肺炎 (Mycoplasma pneumoniae pneumoniae) 的肺炎表现为流行性-流行性循环.
- 由于COVID-19的流行病措施导致疾病发病率显著下降.
- 全球Mycoplasma pneumoniae感染的复苏始于2023年9月.
研究的目的:
- 为了报告当前的流行病Mycoplasma pneumoniae肺炎.
- 突出诊断方法和抗菌素耐药性模式.
主要方法:
- 诊断依赖于呼吸道样本的聚合酶链反应 (PCR) 测试.
- 对Mycoplasma pneumoniae感染的监测和对宏类药物耐药率的监测.
主要成果:
- 全球范围内,一种新的Mycoplasma pneumoniae流行病浪潮正在影响儿童和成年人群.
- 该细菌通过气溶和密切接触传播,导致各种呼吸道和肺外症状.
- 欧洲的宏体耐药率仍然很低,与亚洲观察到的高率形成鲜明对比.
结论:
- 由于其具有流行病潜力,Mycoplasma pneumoniae对公众健康造成了重大关注.
- PCR测试是微生物学诊断的标准.
- 欧洲较低的宏类抗药性表明,这些抗生素在治疗中仍然有效.
更多相关视频
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
15.0K
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
2.3K
相关概念视频
01:30Pneumonia I: Introduction
211
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
211
01:30Pneumonia III: Complications and Assessment
170
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
170
01:29Pneumonia II: Pathophysiology
217
The pathophysiology of pneumonia involves the following steps:
217
01:24Bacterial Phylum Tenericutes
The phylum Tenericutes, which includes the single class Mollicutes, comprises bacteria that lack cell walls. The term "Mollicutes" derives from the Latin word mollis, meaning "soft." These organisms are among the smallest known and are commonly referred to as mycoplasmas due to the prominence of the genus Mycoplasma, which includes well-known human pathogens. Despite their inability to stain gram-positively (a result of their lack of cell walls), mycoplasmas are phylogenetically related to the...
00:57Viral Recombination
23.3K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.3K
01:28Pneumonia IV: Management
299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299